A Pilot Study to Evaluate Novel Agents (Temozolomide and Cixutumumab [IMC-A12 Anti-IGF-IR Monoclonal Antibody IND #100947 NSC #7424601]) in Combination with Intensive Multi-Agent Interval Compressed Therapy for Patients with High-Risk Rhabdomyosarcoma
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
In this study researchers want to find out what effects using IMC A12 in combination with high intensity chemotherapy will have on subjects with high risk rhabdomyosarcoma.
Description
In this study researchers want to find out what effects using IMC A12 in combination with high intensity chemotherapy will have on subjects with high risk rhabdomyosarcoma.
Details
| Condition | Rhabdomyosarcoma |
|---|---|
| Age | 100years or below |
| Clinical Study Identifier | TX2001 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.